EU/3/06/373: Orphan designation for the treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects

Mecasermin

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2017 at the end of the 10-year period of market exclusivity.

On 22 May 2006, orphan designation (EU/3/06/373) was granted by the European Commission to Tercica Europe Limited, Ireland, for mecasermin for the treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects. The sponsorship was transferred to Tercica Europe Limited, Ireland, in December 2005 and subsequently to Ipsen Pharma, France, in July 2009.

Mecasermin has been authorised in the EU as Increlex since 3 August 2007.

Key facts

Active substance
Mecasermin
Medicine name
Increlex
Intented use
Treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects
Orphan designation status
Expired
EU designation number
EU/3/06/373
Date of designation
22/05/2006
Sponsor

Ipsen Pharma
65 Quai Georges Gorse
92100 Boulogne-Billancourt
France
Tel. +33 1 58 33 54 38
http://www.ipsen.com/en/contact-us/

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating